Form D · Other
Vesalius Longevity Labs (Canada) Inc.
Vancouver, A1 · CIK 0002074113
Offering snapshot reported Jun 30, 2025 · SEC filing
- Reported sold
- $168K Offering amount: $168K
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 23, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 30, 2025 | Initial | $168,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-550332
Total Offering Amount represents the price of 8,400,000 common shares at $0.02 per share.
Source: Form D, filed Jun 30, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Shannon Anderson | Director, Executive |
| C. Frank I. Dunsford | Executive |
| Joel Leonoff | Director |
| Shannon Louden | Executive |
| Mark Patricof | Director |
| Kevin Rabbitt | Director, Executive |
| Richard Serbin | Director |
| Timmothy Eve Stump | Executive |
| Jason Suslak | Executive |
Issuer details
Industry: Other (See others in industry)
Address:
1500 1055 West Georgia Street
Vancouver, A1, V6E 4N7
Vancouver, A1, V6E 4N7